Sumitomo Chemical Co. Ltd. (TYO:4005) is endeavoring to get its return on investment (ROI) to at least 7 percent for…...
Please subscribe to read the full story.
Cynapsus Therapeutics
Industry Outlook 2017: Pharmaceuticals Part 2 – M&As
Long-listed drugs often stem from low molecular drugs that have been an important source of revenue for pharmaceutical manufacturers. Being…...
Please subscribe to read the full story.
Sumitomo Dainippon Pharma to Acquire Canadian Biotechnology Company
Sumitomo Dainippon Pharma Co. Ltd. (TYO:4506) announced on Sep. 1, 2016, that its U.S. subsidiary Sunovion Pharmaceuticals Inc. will acquire…...
Please subscribe to read the full story.
